Order Article Reprints

Nagata S, Yamasaki R, Takase EO, Iida K, Watanabe M, Masaki K, Wijering MHC, Yamaguchi H, Kira J-i, Isobe N. Iguratimod Ameliorates the Severity of Secondary Progressive Multiple Sclerosis in Model Mice by Directly Inhibiting IL-6 Production and Th17 Cell Migration via Mitigation of Glial Inflammation. Biology. 2023; 12(9):1217. https://doi.org/10.3390/biology12091217

Nagata, Satoshi, Ryo Yamasaki, Ezgi Ozdemir Takase, Kotaro Iida, Mitsuru Watanabe, Katsuhisa Masaki, Marion Heleen Cathérine Wijering, Hiroo Yamaguchi, Jun-ichi Kira, and Noriko Isobe. 2023. "Iguratimod Ameliorates the Severity of Secondary Progressive Multiple Sclerosis in Model Mice by Directly Inhibiting IL-6 Production and Th17 Cell Migration via Mitigation of Glial Inflammation" Biology 12, no. 9: 1217. https://doi.org/10.3390/biology12091217

Nagata, S., Yamasaki, R., Takase, E. O., Iida, K., Watanabe, M., Masaki, K., Wijering, M. H. C., Yamaguchi, H., Kira, J.-i., & Isobe, N. (2023). Iguratimod Ameliorates the Severity of Secondary Progressive Multiple Sclerosis in Model Mice by Directly Inhibiting IL-6 Production and Th17 Cell Migration via Mitigation of Glial Inflammation. Biology, 12(9), 1217. https://doi.org/10.3390/biology12091217